Redeye provides a short comment on this morning’s Q4 report from Ortoma.
Redeye saw sales that were above and results that were below our expectations.
Sales +110%, adj. EBIT SEK -0.5m vs. ABGSCe Some more revenue recognised in this quarter, order book...
Redeye leaves a comment following the recent announcement by Faron stating that the company is in se...
Redeye slightly raises estimates and fair value range following a strong Q4 from Stille where sales ...
GP margins holding up better than peers Timing of rise in consumer confidence to determine 2024 star...
Marginal estimate changes Gross margin improvements still on the horizon '24e-'25e lease adj.
Redeye revises its estimates and valuation on the back of the Q4 2023 report, which came in below ou...
Redeye remains confident on the case as we believe Impact Coatings is on the right track in its inte...
Redeye revises our forecast following TH1NG’s Q4 2023 report.
Tillväxtresan intakt EQL Pharma ökade de återkommande intäkterna med 25,2 procent, trots tuffare jäm...
Avslutar året i linje med våra estimat Omsättningen i kvartalet uppgick till 70,4 mkr vilket motsvar...
Arctic Blue Beverages har publicerat bolagets delårsrapport för det fjärde kvartalet år 2023.
Advenica close 2023 with a 25% increase in sales, primarily driven by substantial gains in the Desi...
Fortsatt stark tillväxt y/y Omsättningen i Q4 uppgick till 27,2 mkr, vilket motsvarar en tillväxt om...
Sales in line, but 10% EBIT beat We lift '24e adj. EBIT 8% on lower opex assumptions +17% adj.
I dag offentliggjorde Spotlight Group sin bokslutskommuniké för 2023.
Exel’s Q4 figures remained very low as account activity is only now bottoming out after a challengin...
Omsättningen i det fjärde kvartalet kom in i linje med Analysguidens förväntningar men resultat pres...
Ahead of Atria’s Q4, due on 22 February, we maintain our estimates intact.
